Physician profile
Patrick Ryan Higgins
NPI 1235472507
$3,374.78
in general payments reported to CMS, 2019-2025
22 companies · $990 in 2025
The $990 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.91 · 2021: $189 · 2022: $308 · 2023: $798 · 2024: $1,077 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Travel and Lodging: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.09 |
| Travel and Lodging | $432.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $578.97 | 2023-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $563.02 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $546.25 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Actelion Pharmaceuticals US, INC. | $479.00 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.32 | 2021-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $158.19 | 2021-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $107.23 | 2023-2025 | Wakix |
| Insmed, INC. | $68.53 | 2023-2024 | Arikayce |
| Genzyme Corporation | $68.10 | 2024-2025 | |
| Verona Pharma, INC. | $55.05 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $45.78 | 2024-2025 | Glassia |
| Merck Sharp & Dohme LLC | $42.11 | 2024-2025 | Keytruda, Zerbaxa |
| Amgen INC. | $32.44 | 2024-2025 | Tezspire |
| Electromed, INC. | $31.84 | 2024 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $29.72 | 2025 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.88 | 2024 | |
| Lilly USA, LLC | $17.04 | 2025 | Zepbound |
| Viatris Specialty LLC | $14.48 | 2025 | Yupelri |
| Inogen, INC. | $14.03 | 2023 | Inogen At Home Stationary Concentrator |
| Grifols USA, LLC | $13.83 | 2024 | Prolastin-C Liquid |
| La Jolla Pharmaceutical Company | $12.97 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.